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Abstract
Background: We have previously identified Urokinase Plasminogen Activator Receptor (PLAUR)
as an asthma susceptibility gene. In the current study we tested the hypothesis that PLAUR single
nucleotide polymorphisms (SNPs) determine baseline lung function and contribute to the
development of Chronic Obstructive Pulmonary Disease (COPD) in smokers.
Methods: 25 PLAUR SNPs were genotyped in COPD subjects and individuals with smoking history
(n = 992). Linear regression was used to determine the effects of polymorphism on baseline lung
function (FEV1, FEV1/FVC) in all smokers. Genotype frequencies were compared in spirometry
defined smoking controls (n = 176) versus COPD cases (n = 599) and COPD severity (GOLD
stratification) using logistic regression.
Results:  Five SNPs showed a significant association (p < 0.01) with baseline lung function;
rs2302524(Lys220Arg) and rs2283628(intron 3) were associated with lower and higher FEV1
respectively. rs740587(-22346), rs11668247(-20040) and rs344779(-3666) in the 5'region were
associated with increased FEV1/FVC ratio. rs740587 was also protective for COPD susceptibility
and rs11668247 was protective for COPD severity although no allele dose relationship was
apparent. Interestingly, several of these associations were driven by male smokers not females.
Conclusion: This study provides tentative evidence that the asthma associated gene PLAUR also
influences baseline lung function in smokers. However the case-control analyses do not support
the conclusion that PLAUR is a major COPD susceptibility gene in smokers. PLAUR is a key serine
protease receptor involved in the generation of plasmin and has been implicated in airway
remodelling.
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Background
Chronic Obstructive Pulmonary Disease (COPD) and
asthma are complex respiratory diseases involving both
genetic and environmental factors (e.g. smoking exposure
in COPD, allergen exposure in asthma) [1,2]. Using 587
asthma families we have recently fine mapped a 14.4 Mb
region on Chromosome 19q13 and identified the uroki-
nase plasminogen activator receptor (PLAUR, plasmino-
gen activator receptor, urokinase type, alternative
symbols; UPAR and CD87) gene as an asthma susceptibil-
ity gene [3]. Importantly, we also demonstrated that pol-
ymorphisms spanning PLAUR predict decline in forced
expiratory volume in 1 second (FEV1) in asthma subjects
and determine plasma PLAUR levels [3]. PLAUR plays a
key role in the formation of the serine protease plasmin by
interacting with urokinase plasminogen activator (PLAU)
[4] and has been implicated in many processes including;
cell differentiation, proliferation and migration [5]. Plas-
minogen activator inhibitors (PAI-1 and PAI-2) regulate
PLAUR activity [6].
While asthma and COPD are distinct clinical entities, a
common feature of both diseases is airway remodelling,
i.e. deposition of extracellular matrix (ECM) in the sub-
mucosa, thickening of the reticularis and smooth muscle
hyperplasia [7,8]. From the known biology of PLAUR, this
protease receptor is potentially involved in these processes
due to its role in matrix metalloproteinase (MMP) and
transforming growth factor (TGF)β1 activation and tissue
fibrosis [5].
Whole genome linkage analyses using the Boston early
onset COPD family cohort has identified linkage to chro-
mosome 19q13 for FEV1, FVC and FEV1/FVC, LOD 1.40
(59 cM), 1.20 (101 cM), 1.47 (61 cM) respectively [9].
Typing additional markers on 19q13 provided further
support for this region i.e. FEV1 and FEV1/FVC LOD 1.73
(62 cM), 1.70 (62 cM) which was strengthened by selec-
tion of former/current smokers, LOD 3.30 (71 cM) and
1.96 (63 cM) respectively [10]. The PLAUR gene is located
at 67 cM and based on genetic and biological evidence
may be a COPD susceptibility gene. Smoking is associated
with an increased decline in FEV1 and is a major risk factor
for the development of COPD [11] therefore we investi-
gated the role of PLAUR SNPs in smokers.
The aim of the current study was to test the hypotheses
that a) polymorphisms spanning PLAUR  contribute to
COPD susceptibility and severity in smokers and b) that
these polymorphisms influence baseline lung function
(FEV1 and FEV1/FVC) in smokers. We have genotyped 27
SNPs spanning PLAUR in a cohort recruited for COPD or
smoking history (n = 992 subjects) and completed a series
of association analyses. We provide tentative evidence
that polymorphisms spanning PLAUR influence baseline
lung function but do not support the conclusion that
PLAUR is a major COPD susceptibility gene in smokers.
Methods
Subjects and Clinical Assessment
The subjects were recruited from five UK centres for smok-
ing history and/or COPD diagnosis (Table 1). 537 sub-
jects were collected in Nottingham, Caucasian > 40 years
and smoking >10 pack years or other centres (n = 455)
recruited for spirometry defined COPD confirmed by a
physician, Caucasian > 45 years old and smoking >10
pack years. The combined population (n = 992) recruited
for smoking history or COPD diagnosis were stratified
into healthy smokers (n = 176, post bronchodilator (BD,
salbutamol) FEV1 > 80% and postBD FEV1/FVC > 0.7) and
COPD subjects (n = 599, post BD FEV1 < 80% and postBD
FEV1/FVC < 0.7). Subjects without data or not meeting
Table 1: Baseline characteristics of study cohorts
Smokers
(n = 992)
Controls
(n = 176)
COPD
(n = 599)
Male Smokers
(n = 553)
Female Smokers
(n = 431)
Age in years
(mean ± SD)
63.33 ± 10.28 (992) 54.38 ± 9.52 65.96 ± 9.01 64.98 ± 10.01 61.23 ± 10.32
Female (%) 43.8 (984) 56.3 40.4 0 100
% predicted FEV1
(mean ± SD)
56.01 ± 28.17 (975) 96.03 ± 12.15 40.31 ± 15.63 52.82 ± 26.87 60.24 ± 29.43
FEV1/FVC Ratio
(mean ± SD)
55.3 ± 17.4 (971) 77.3 ± 5.9 46.3 ± 12.6 53.7 ± 17.3 57.5 ± 17.5
Post BD % predicted FEV1
(mean ± SD)
59.08 ± 27.14 (885) 99.48 ± 11.72 44.65 ± 15.52 55.34 ± 25.46 64.10 ± 28.55
Post BD FEV1/FVC Ratio
(mean ± SD)
55.6 ± 17.7 (873) 79.1 ± 5.5 46.2 ± 12.0 53.2 ± 17.6 58.6 ± 17.6
Pack Years
(mean ± SD)
43.52 ± 26.05 (969) 32.74 ± 20.04 47.61 ± 27.01 48.72 ± 28.53 36.65 ± 20.66
FEV1 Forced expiratory volume in one second, FVC forced vital capacity. Number in brackets represents data available for that variable. Continual 
variables between Controls and COPD groups were compared by independent T-Test, categorical variables by Pearson chi square (all variables p < 
0.0001). Similarly, all variables between males and females were statistically different.BMC Medical Genetics 2009, 10:112 http://www.biomedcentral.com/1471-2350/10/112
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these criteria were excluded from the case control analy-
ses. COPD severity was investigated using post bron-
chodilator spirometry, i.e. GOLD classification [12] (n =
643, Additional file 1). Ethical approval was obtained
from local ethics committees (Nottingham, Sheffield,
Manchester, Leicester, Oxford). Informed Consent from
all subjects was obtained.
SNP selection and Genotyping
The Human PLAUR gene has been sequenced in 46 Cau-
casian individuals (SeattleSNPs, http://pga.mbt.washing
ton.edu/). SNPs were chosen for inferred function or their
ability to tag Linkage Disequlibrium (LD) blocks ([3],
Table 2). CEPH genotyping data from the HapMap project
(B34) in conjunction with Haploview software (v3.3) was
used to identify tagging SNPs within the gene (R2 0.8,
Minor Allele Frequency (MAF) 0.1) or 5'distal region (R2
0.75, MAF 0.2) [13]. SNPs were genotyped by Kbio-
sciences (Hitchin, UK) using genomic DNA. Hardy-Wein-
berg Equilibrium was assessed using Haploview software
[13].
Statistical Analyses
Using SPSS (version 15, SPSS Inc., Chicago, IL) logistic
regression analyses were completed for dichotomous
traits using additive (e.g. AA vs. AC vs. CC), recessive (AA/
AC vs. CC) or dominant (AA vs. AC/CC) models. The
COPD susceptibility analyses included, age, sex and pack
years as covariates (Table 1) and the GOLD 1 versus 4
analyses included age as a covariate. Unadjusted contin-
gency table analyses were completed using genotype or
allele models (GraphPad Prism version 5, San Diego, CA).
Linear regression determined the contribution of each
SNP to baseline FEV1 (litres) or FEV1/FVC ratio using addi-
tive, recessive or dominant models including; age, sex,
height and smoking pack years as covariates. Haploview
software was used to identify PLAUR haplotypes. A p <
0.01 was considered significant for all analyses.
5'region analyses
Basal promoter activity of PLAUR has been mapped to
220 bp upstream of the start codon [14]. Using DNA from
31 Caucasian subjects a 4 kb promoter region was ampli-
fied and sequenced (Applied Biosystems, UK). SNPs were
analysed for transcription factor (TF) binding site changes
using online databases as described [15].
Table 2: Gene location and minor allele frequencies of PLAUR SNPs genotyped
No. SNP Location in PLAUR Alleles Selected for: Smokers Controls COPD
1 rs4803648 3'UTR A/T LDtSNP 0.20 0.19 0.19
2 rs4802189 3'UTR A/C LDtSNP 0.16 0.16 0.15
3 rs4251953 3'UTR/intron G/A LDtSNP 0.04 0.05 0.04
4 rs4251938 3'UTR/intron A/G LDtSNP 0.12 0.12 0.11
5 rs4251923 3'UTR/intron G/A 3'UTR 0.04 0.02 0.04
6 rs4760 Exon 7 T/C Pro317/272Leu, LDtSNP 0.16 0.17 0.15
7 rs2302524 Exon 6 T/C Lys220/175Arg LDtSNP 0.16 0.16 0.15
8 rs4251864 Intron 3 T/C LDtSNP 0.09 0.09 0.08
9 rs2239372 Intron 3 G/A LDtSNP 0.50 0.48 0.51
10 rs2283628 Intron 3 T/C LDtSNP 0.18 0.18 0.18
11 rs4251846 Intron 3 C/T LDtSNP 0.12 0.11 0.13
12 rs2239374 Intron 3 C/T LDtSNP 0.18 0.19 0.17
13 rs2286960 Intron 1 C/T LDtSNP 0.24 0.28 0.23
14 rs4251805 5'UTR-119 G/A Promoter 0.04 0.03 0.04
15 rs344781 5'UTR-466 T/C Promoter 0.23 0.29 0.29
16 rs2356338 5'UTR-649 G/T Promoter 0.28 0.29 0.29
17 rs344780 5'UTR-3545 C/T Promoter 0.23 0.20 0.22
18 rs344779 5'UTR-3666 G/T LDtSNP 0.39 0.40 0.37
19 rs8113334 5'UTR-6873 T/C LDtSNP 0.19 0.19 0.19
20 rs4493171 5'UTR-10534 C/T LDtSNP 0.22 0.19 0.23
21 rs7259340 5'UTR-12331 C/A LDtSNP 0.36 0.37 0.34
22 rs11668247 5'UTR-20040 C/T LDtSNP 0.39 0.43 0.37
23 rs346043 5'UTR-20459 T/C LDtSNP 0.26 0.26 0.27
24 rs740587 5'UTR-22346 T/C LDtSNP 0.45 0.49 0.42
25 rs346054 5'UTR-30147 C/G LDtSNP 0.45 0.47 0.46
Number 992 176 599
LDtSNP = LD tagging SNPBMC Medical Genetics 2009, 10:112 http://www.biomedcentral.com/1471-2350/10/112
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Results
Clinical Characteristics and Allele Frequencies
Baseline features of the COPD cases (n = 599) and con-
trols (n = 176) are shown in Table 1. As anticipated base-
line FEV1 and FEV1/FVC of the smoking controls and
COPD cases are significantly different (p < 0.0001). Com-
parison of other baseline features between controls and
cases identified significant differences for age, sex and
pack years, therefore in subsequent analyses we adjusted
for these variables. Also shown are the baseline features of
male and female smokers which show that females have
significantly less smoking exposure and increased lung
function compared to male subjects (p < 0.001). SNPs
spanning PLAUR were genotyped (Table 2). Two of the 27
SNPs, rs1994417 and rs4251831 showed deviation from
Hardy-Weinberg equilibrium (p = 0.028 and p = 0.004
respectively) in the entire population (n = 992). These
SNPs were removed from subsequent analyses.
Haplotype structure
The haplotype structure of the PLAUR region generated
using all data is shown in Figure 1. These data revealed
that there is some redundancy in the genotyping (as
expected) and that there is a block of Linkage Disequilib-
Schematic representation of the PLAUR gene and haplotype block structure of PLAUR SNPs in smokers Figure 1
Schematic representation of the PLAUR gene and haplotype block structure of PLAUR SNPs in smokers. (A) 
Schematic representation of the PLAUR gene on chromosome 19 illustrating the position of SNPs 1-13 (see Table 2). SNPs 14-
25 located in the promoter region/5'region are omitted for clarity. The PLAUR gene is displayed in the reverse orientation to 
that observed on chromosome 19 (~40 kb). Exons are depicted as open boxes except for alternatively spliced exon 7 (VIIB, 
grey, see [34]). (B) Haplotype block structure of all 25 SNPs on Chromosome 19 in smokers (n = 992). The colour of shading 
represents R2 (a measure of LD) and numerical values are given (generated using Haploview software [13]). Haplotype blocks 
were defined using confidence intervals for strong LD D' 0.7-0.98.
 
 
 
                5’                                               3’ 
                                                 13                                   12    11   10    9       8                                              7                    6   5     4   3              2   1    
A
 
 
 
 
 
 
      I         II                 III                                                            IV    V                     VI                  VIIA           VIIB 
 Exon length (bp)    285       111     144                162  135      147               564          430  
Intron length (bp)      2374    2121  8675         905  3067  3081        2031
BBMC Medical Genetics 2009, 10:112 http://www.biomedcentral.com/1471-2350/10/112
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rium (LD) in the 3'region, a region of low LD spanning
the gene and several blocks of LD in the 5'region (Figure
1).
PLAUR SNPs and COPD susceptibility in smokers
Analyses of the smoking control cohort (n = 176) versus
the COPD cohort (n = 599) identified only one SNP meet-
ing statistical significance (p < 0.01), i.e. rs740587(-
22346) showed a protective effect for COPD susceptibility
(Table 3). Several other SNPs showed borderline signifi-
cance including SNPs in intron 1 (rs2286960, protec-
tive(P)) and in the 5'region i.e. rs344779(-3666, P),
rs11668247(-20040, P) and rs346054(-30147, P). These
data provide limited evidence that PLAUR SNPs are asso-
ciated with COPD susceptibility per se.
PLAUR SNPs do not show association with spirometry 
defined COPD severity
Subjects were stratified according to GOLD criteria (Addi-
tional file 1) and unadjusted analyses comparing GOLD
groups 1, 2, 3 and 4 and extreme severity (GOLD 1 versus
4, adjusted for age) were completed. GOLD Stage 1-4
analyses did not identify any SNPs showing significant
association. Adjusted analyses (age) of GOLD Stage 1 and
Stage 4 using logistic regression identified
rs11668247(5'UTR-20040) as a protective allele (domi-
nant model OR 0.32 CI 0.14-0.77, p = 0.011) (Additional
file 1).
PLAUR SNPs influence baseline lung function in smokers
In addition to dichotomous trait analyses based on post
bronchodilator spirometry we also investigated the role of
PLAUR SNPs in determining baseline lung function, FEV1
and FEV1/FVC ratio in the entire population (n = 992)
(Figure 2 and Additional file 2). The FEV1 analyses identi-
fied two SNP associations; rs2302524(Lys220Arg) was
associated with lower FEV1 and rs2283628 (intron 3) was
associated with higher FEV1 (Figure 2). Both associations
were driven by carriers of two variant alleles (recessive
model p = 0.006 and p = 0.008 respectively).
In the baseline FEV1/FVC analyses three SNPs showed
association,  i.e. rs740587(5'UTR-22346),
rs11668247(5'UTR-20040) and rs344779(5'UTR-3666)
Table 3: Risk of COPD in smokers and PLAUR SNPs
Controls
(n = 176)
COPD
(n = 599)
Additive Recessive Dominant
SNP 0 1 2 0 1 2 p-value Odds 
ratio
95%CI p-value Odds 
ratio
95%CI p-value Odds 
ratio
95%CI
rs4803648 112 48 9 381 180 21 0.963 1.01 0.70-1.45 0.313 0.60 0.23-1.61 0.637 1.11 0.72-1.70
rs4802189 117 47 4 420 151 12 0.964 0.99 0.66-1.48 0.735 0.79 0.20-3.13 0.955 1.01 0.65-1.59
rs4251953 158 15 1 540 43 2 0.800 0.92 0.49-1.74 0.825 1.38 0.08-24.45 0.742 0.89 0.45-1.77
rs4251938 133 38 1 466 116 8 0.969 0.99 0.63-1.56 0.656 1.70 0.17-17.27 0.883 0.96 0.59-1.57
rs4251923 166 8 0 544 44 0 0.598 1.28 0.52-3.16 ND ND ND 0.598 1.28 0.52-3.16
rs4760 122 38 10 429 146 13 0.271 0.81 0.56-1.18 0.106 0.42 0.15-1.20 0.523 0.86 0.55-1.36
rs2302524 121 54 1 422 149 16 0.691 0.92 0.63-1.37 0.081 7.23 0.78-66.86 0.293 0.79 0.51-1.22
rs4251864 143 30 1 507 81 5 0.976 1.01 0.61-1.66 0.480 2.38 0.22-26.30 0.876 0.96 0.56-1.64
rs2239372 48 84 41 150 284 156 0.679 1.06 0.80-1.40 0.857 1.04 0.66-1.66 0.621 1.12 0.71-1.76
rs2283628 122 43 10 396 172 23 0.822 0.96 0.67-1.38 0.118 0.47 0.18-1.21 0.706 1.09 0.71-1.67
rs4251846 141 31 3 452 134 8 0.518 1.16 0.74-1.82 0.380 0.50 0.11-2.34 0.340 1.27 0.78-2.08
rs2239374 115 57 4 401 173 15 0.379 0.85 0.59-1.23 0.785 0.84 0.25-2.88 0.369 0.83 0.54-1.26
rs2286960 91 71 13 347 215 30 0.022 0.68 0.49-0.95 0.049 0.45 0.20-0.99 0.061 0.68 0.45-1.02
rs4251805 163 11 0 538 46 1 0.323 1.49 0.68-3.30 ND ND ND 0.340 1.48 0.66-3.30
rs344781 110 50 13 358 191 33 0.719 1.06 0.76-1.49 0.729 0.86 0.38-1.97 0.534 1.14 0.75-1.74
rs2356338 90 69 16 282 271 38 0.397 1.15 0.83-1.60 0.685 0.85 0.39-1.86 0.215 1.29 0.86-1.92
rs344780 107 42 11 341 180 31 0.611 1.10 0.77-1.56 0.729 0.86 0.36-2.06 0.422 1.197 0.77-1.86
rs344779 65 78 33 229 287 74 0.097 0.78 0.58-1.05 0.029 0.54 0.31-0.94 0.437 0.85 0.57-1.28
rs8113334 120 47 9 397 172 24 0.969 1.01 0.71-1.44 0.478 0.71 0.27-1.85 0.729 1.08 0.70-1.66
rs4493171 114 53 7 348 215 28 0.204 1.26 0.88-1.79 0.768 1.16 0.44-3.09 0.165 1.34 0.89-2.04
rs7259340 70 77 26 251 263 69 0.147 0.80 0.60-1.08 0.155 0.65 0.36-1.18 0.299 0.81 0.54-1.21
rs11668247 67 68 41 241 267 87 0.034 0.74 0.56-0.98 0.022 0.55 0.34-0.92 0.172 0.75 0.50-1.13
rs346043 94 66 12 305 251 36 0.279 1.20 0.86-1.67 0.836 1.09 0.48-2.48 0.221 1.28 0.86-1.92
rs740587 54 72 50 206 272 110 0.010 0.70 0.53-0.92 0.016 0.56 0.35-0.90 0.056 0.66 0.43-1.01
rs346054 59 69 48 171 296 124 0.293 0.86 0.66-1.14 0.011 0.55 0.35-0.87 0.509 1.15 0.76-1.77
0, 1, 2 represent number of genotypes for major, heterozygote and minor genotypes respectively. For minor allele frequencies in controls versus 
COPD cases see Table 2. Logistic regression was used to compare genotype frequencies using the additive, recessive, and dominant models with 
covariates age, sex and pack years included in the model. ND = Not determined (minor allele frequency too low).BMC Medical Genetics 2009, 10:112 http://www.biomedcentral.com/1471-2350/10/112
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in the 5'region were significantly associated with
improved FEV1/FVC ratio (Figure 2, Additional file 2).
Borderline significance was also observed for
rs344781(5'UTR-466) and rs2283628(intron 3) for
higher baseline FEV1/FVC values and rs346043(5'UTR-
204590) and rs2356338(5'UTR-649) for reduced baseline
FEV1/FVC values. These data highlight the potential
importance of genetic determinants in the 5'region partic-
ularly for the FEV1/FVC phenotype. In order to determine
if males or females are driving these associations with
lung function we completed gender specific analyses for
the key associated SNPs (Additional file 2). The baseline
features of the male and female only cohorts are shown in
Table 1. These data suggested that both the
rs740587(5'UTR-22346) and rs344779(5'UTR-3666)
associations with FEV1/FVC are driven by males as the
allele dose effect observed in all subjects is present in male
subjects and is lost in females e.g. rs344779 FEV1/FVC
data for males; GG 51.8 ± 1.2 (185), GT 54.5 ± 1.0 (260),
TT 59.1 ± 2.0 (66) p = 0.007 versus females; GG 56.8 ± 1.4
(146), GT 57.7 ± 1.2 (195), TT 59.5 ± 1.8 (66), p = 0.531.
PLAUR promoter analyses identifies novel SNPs with 
predicted function
As several associations were located in the 5'region we
sequenced 4000 bps of the key promoter region (LD block
2, Figure 1) in 37 Caucasian subjects to identify novel var-
iation. A further five novel and two reported polymor-
phism were identified (Additional file 3). The 12
polymorphisms were in high LD (data not shown) which
suggested identification of causative polymorphisms will
be difficult. Nonetheless, we conducted a bioinformatics
analysis and three of these polymorphisms were found to
generate binding sites for the E26 transforming sequence
(ets) family transcription factor binding sites. Multiple
potential changes in transcription factor (TF) binding sites
were observed for SNPs in the 5' distal region e.g. altera-
tions in hypoxia inducible factor 1 binding sites (Addi-
tional file 3).
PLAUR SNPs are associated with baseline FEV1 and FEV1/FVC Figure 2
PLAUR SNPs are associated with baseline FEV1 and FEV1/FVC. Regression analysis was used to investigate the associ-
ation between PLAUR SNPs and baseline FEV1 and FEV1/FVC ratio using the additive, recessive or dominant models. Data rep-
resent mean ± standard error. Covariates included in the model included age, gender, height and pack years. A = Additive, R = 
Recessive, D = Dominant models showing p < 0.01 are presented.
AR R
AR R ARDBMC Medical Genetics 2009, 10:112 http://www.biomedcentral.com/1471-2350/10/112
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Discussion
This study provides preliminary evidence that SNPs
within PLAUR influence baseline lung function in smok-
ers, however does not support the conclusion that PLAUR
SNPs contribute significantly to the multiple genetic fac-
tors that predispose smokers to develop COPD.
We have previously identified PLAUR as an asthma and
lung function associated gene and in particular identified
the 3'region (rs4803648, rs4802189), intron 3
(rs2239372) and 5'region (rs2356338, rs4493171,
rs346043) as determinants [3]. PLAUR  SNPs predicted
decline in FEV1 in asthma subjects and were associated
with PLAUR levels in plasma [3] (see Table 4). These data
and the emerging role of PLAUR in tissue remodelling
suggested PLAUR may also influence COPD susceptibility
in smokers. To test this hypothesis we genotyped 27 SNPs
spanning PLAUR in a cohort of 992 smokers recruited for
smoking history and/or COPD diagnosis, 25 SNPs passed
quality control. Data from all subjects identified multiple
5'region LD blocks, a region of low LD spanning the gene
and a 3'region LD block in keeping with our previous data
[3].
In our first analyses we determined if PLAUR SNPs are risk
factors for the development of spirometry defined COPD.
These data identified only one SNP association (p < 0.01)
i.e. rs740587 in the 5'region was protective however mul-
tiple borderline associations were observed particularly
for additional SNPs in the promoter/5'region. We have
previously shown that asthma risk alleles span the entire
PLAUR gene including the 5'region, intron 3 and 3'region
(Table 4, [3]). There was no direct concordance between
asthma and COPD risk alleles and our data does not sup-
port the conclusion that PLAUR SNPs are major risk fac-
tors for the development of COPD in smokers.
The finding that the only signal for COPD susceptibility
maps to the 5'region is of interest due to the observation
that soluble PLAUR is elevated seven fold in the sputum
of COPD patients [16] suggesting mechanisms underlying
disease association may at least in part involve altered
PLAUR transcription. In agreement with this hypothesis a
recent study identified PLAUR mRNA expression in lung
tissue as a marker of COPD and showed a significant cor-
relation between FEF25-75(%Pred) and PLAUR mRNA
expression (r = -0.44) [17].
Table 4: Concordance between asthma analyses and the current study
SNP Allele *Asthma 
Susceptibility
Decline in 
FEV1 in 
asthma
*Serum 
PLAUR
COPD 
Susceptibility
COPD 
Severity
(GOLD 1/4)
Baseline 
FEV1
Baseline 
FEV1/FVC
rs4803648 T Risk Accelerated - - - - -
rs4802189 C Risk Accelerated - - - - -
rs4251953 A - Accelerated - - - - -
rs4251938 G Risk - - - - - -
rs4251923 A - - - - - - -
rs4760 C - Slowed - - - - -
rs2302524 C Risk Accelerated - - - Decreased -
rs4251864 C - - - - - - -
rs2239372 A Risk - Increased - - - -
rs2283628 C - - - - - Increased -
rs4251846 T - - - - - - -
rs2239374 T - - - - - - -
rs2286960 T - Slowed - - - - -
rs4251805 A - - - - - - -
rs344781 C - NA - - - - -
rs2356338 T Risk Accelerated Increased - - - -
rs344780 T - - - - - - -
rs344779 T - - - - - - Increased
rs8113334 C -- - - - - - -
rs4493171 T Protection - Decreased - - - -
rs7259340 A - - - - - - -
rs11668247 T - - - - Protection - Increased
rs346043 C Risk Accelerated Increased - - - -
rs740587 C - - - Protection - - Increased
rs346054 G - - - - - - -
*Significant Family Based Association Test (FBAT) results from our previous study.[3] using three asthma family cohorts from Nottingham, 
Southampton and The Netherlands (n = 587 families). The asthma patients that were probands of the Dutch asthma families (n = 200) were 
longitudinally followed in the Netherlands for approximately 30 years (1965-1995). FEV1 decline over time was modelled. FEV1 forced expiratory 
volume in one second; FVC forced vital capacity. NA = Not available.BMC Medical Genetics 2009, 10:112 http://www.biomedcentral.com/1471-2350/10/112
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COPD severity analyses based on GOLD classification did
not identify any SNP showing association. Additional
analysis of extremes of severity (GOLD 1 versus 4) again
highlighted a role for rs11668247 in the 5'region in keep-
ing with the COPD susceptibility analyses suggesting a
modest influence of the distal 5'region SNPs.
In order to extend our case/control analyses we investi-
gated the role of PLAUR SNPs in determining baseline
lung function in this cohort. These analyses identified sev-
eral significant associations; rs2302524(Lys220Arg) and
rs2283628 (intron 3) were associated with lower and
higher FEV1  respectively. rs740587(5'UTR-22346),
rs11668247(5'UTR-20040) and rs344779(5'UTR-3666)
in the 5'region were all associated with increased FEV1/
FVC ratio. Interestingly, several SNPs showed very clear
allele dose effects on FEV1/FVC ratio e.g. rs740587(5'UTR-
22346), providing greater confidence in these data. The
magnitude of effect was ~5% change in FEV1/FVC
between genotypes and so potentially these effects are
clinically relevant and surprising for a single SNP in a sin-
gle gene. Interestingly, two of the SNPs associated with
baseline FEV1/FVC were also associated with COPD sus-
ceptibility and severity respectively, i.e. rs740587(5'UTR-
22346) and rs11668247(5'UTR-20040) in the 5'region.
The rs2302524 (Lys220Arg) association with reduced
baseline FEV1 values is of interest as this variant may be
predicted to change the coding sequence of the PLAUR
protein and this polymorphism has previously been asso-
ciated with increased asthma risk and increased decline in
FEV1 in asthma ([3], Table 4) The Lys220Arg is considered
a conservative substitution, however the functional signif-
icance of this finding remains to be resolved. Interestingly,
our data suggests a potential need for both alleles to be
present prior to a physiological effect, i.e. a recessive effect.
It is also important to note that the single SNP associa-
tions reflect the linkage disequilibrium spanning the
PLAUR gene e.g. rs11668247 and rs740587 are both asso-
ciated with increased baseline FEV1/FVC and these SNPs
are in high LD i.e. are inherited together more than by
chance suggesting they both tag or contribute to the cau-
sation mechanism.
For the key associations with lung function we were also
interested to determine if males or females were driving
the associations and therefore completed gender specific
analyses. All baseline features including mean age, smok-
ing pack years and lung function (pre and post bronchodi-
lator FEV1  and FEV1/FVC) were significantly different
between the male and female smokers. These data are in
keeping with a recent study that examined gender specific
differences between subjects with severe emphysema and
again identified less severe airway obstruction in females
[18]. Our data suggest that the rs740587(5'UTR-22346)
and rs344779(5'UTR-3666) associations with FEV1/FVC
are driven by the male subjects as females do not exhibit
the allele dose effect on FEV1/FVC ratio. Interesting, by
selecting male subjects only the magnitude of effect was
also increased i.e. the range of FEV1/FVC between geno-
types for rs344779 for all subjects was 5.1% but for males
was 7.3%, females 2.7%. This would suggest females do
not demonstrate the lower FEV1/FVC ratio in carriers of
the common alleles at these loci. These data are intriguing
and potentially suggest that the effects of the polymor-
phisms in the 5'region are unmasked only in males i.e.
gender specific transcriptional mechanisms. However, it is
also feasible that the SNP effects are only identifiable in
more severe airway obstruction i.e. in the males. This
observation requires further investigation.
Cardiovascular disease including; ischemic heart diseases,
hypertension and myocardial infarction have also been
shown to be a common co-morbidity in COPD [11] and
COPD may be an independent risk factor for the develop-
ment of cardiovascular disease [19]. PLAUR levels have
been associated with vascular remodelling [20] and
monocyte adhesion in acute myocardial infarction [21].
Therefore it is feasible that in the COPD case control anal-
yses we are really testing association with cardiovascular
disease not COPD. While we have not formally tested the
association between PLAUR SNPs and cardiovascular dis-
ease outcomes as we do not have this information, this
seems unlikely. Our data suggests PLAUR SNPs influence
baseline lung function in smokers irrespective of the pres-
ence or absence of COPD. Similarly, we have identified
that PLAUR SNPs are determinants of baseline lung func-
tion in asthmatic children where clearly cardiovascular
disease is not anticipated to confound the analyses [3].
In order to begin to investigate mechanisms underlying
associations we have sequenced 4000 bp of the core pro-
moter and identified a further five novel and two reported
polymorphisms making a total of 12 polymorphisms in
high LD (Additional file 3). Several of these SNPs generate
ets family binding sites. c-ets-1 is of particular interest as
this transcription factor is induced by oxidative stress e.g.
H2O2 [22]. Importantly, H2O2 in breath condensate is ele-
vated in COPD [23] and asthma [24]. These data poten-
tially provide the link between the airway environment
and expression of PLAUR determined by the presence/
absence of SNPs. Interestingly, PLAU and PAI-1 expres-
sion are also elevated in sputum from asthma and COPD
subjects [16] suggesting the plasminogen system may be
augmented in these diseases. Importantly, PLAU and PAI1
transcription is also up regulated by ets-1 [25,26]. Also of
interest is the alteration in Hypoxia Inducible Factor (HIF)
binding sites due to the presence of a polymorphism (e.g.
SNP rs11668247(5'UTR-20040) that was associated with
COPD severity and lung function generates a HIF1 site.BMC Medical Genetics 2009, 10:112 http://www.biomedcentral.com/1471-2350/10/112
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PLAUR transcription has been shown to be increased by
HIF1β under hypoxia conditions [27] which may be a
mechanism involved in epithelial mesenchymal transi-
tion (EMT) [28].
The exact mechanism by which PLAUR contributes to the
underlying pathobiology of the airways remains to be
resolved, however its role in the generation of plasmin
which subsequently leads to ECM degradation, MMP acti-
vation, TGFβ1 activation, 5-lipoxygenase activation and
cell migration implicate tissue remodelling as a key func-
tion [29,30]. The complex role of the PLAU-PLAUR path-
way in the airways is illustrated in Figure 3. It is important
to note that there is accumulating evidence that genetic
polymorphism in genes encoding components of the
PLAU-PLAUR regulatory network constitute risk factors
for the development of COPD e.g. polymorphisms span-
ning Serpin peptidase inhibitor, clade E (SERPINE2) have
shown significant association with COPD susceptibility,
FEV1 and FEV1/FVC [31]. The SERPINE2 gene encodes a
PLAU inhibitor providing further support for the role of
the PLAU-PLAUR pathway in COPD pathogenesis.
The complex role of the PLAU-PLAUR pathway in the airways Figure 3
The complex role of the PLAU-PLAUR pathway in the airways. PLAUR is a complex, multi-domain (D1, 2, 3) mole-
cule and exists as a membrane bound GPI linked protein and in multiple soluble forms. The interaction between PLAU-PLAUR 
is critical for the conversion of plasminogen to plasmin and is regulated by a series of proteins including; PAI-1, PAI-2 and 
SERPINE2 which have previously been implicated in COPD pathogenesis [16,31]. Plasmin has many downstream proteolytic 
effects including those common to remodelling of the airways e.g. MMP activation. In addition PLAUR interacts with several 
membrane receptors leading to the activation of signalling cascades resulting in alterations in; proliferation, migration, adhesion, 
endocytosis and cytoskeletal changes. PLAUR also exists in multiple soluble forms (sPLAUR) generated by splicing and/or pro-
teolytic cleavage implicated in chemotaxis and interactions with the extracellular matrix [5,35,36].BMC Medical Genetics 2009, 10:112 http://www.biomedcentral.com/1471-2350/10/112
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Chromosome 19q13 has previously been investigated for
genetic determinants influencing COPD susceptibility. In
particular one of five tested SNPs spanning Transforming
Growth Factor β1 TGFB1 (at 41.8 Mbp) was associated
with severe COPD in case (n = 304) control (n = 441)
analyses and airway obstruction in family (77 pedigrees)
analyses (p < 0.05) [10]. Similarly, one of four tested SNPs
within latent transforming growth factor beta binding
protein 4, LTB4P (at 41.8 Mbp) was associated (p = 0.01)
with a densiometric emphysema distribution phenotype
(Basal 1/3 lower lobe) [32] but not lung function [33] in
282 and 304 subjects respectively from the National
Emphysema Trial. Overall, therefore the evidence that
TGFB1  and  LTB4P  underlie the linkage with FEV1 and
FEV1/FVC observed to the region is underwhelming.
Importantly, in our asthma analyses we excluded these
regions as containing the main dominants of lung func-
tion using a combination of linkage and association anal-
yses [3]. However, it is also important to note that in
COPD the linkage peak may involve genetic determinants
in multiple genes underlying the signal.
This study extends our asthma association and has several
strengths including extensive evaluation of polymorphic
variation spanning the PLAUR region to examine COPD
susceptibility and the examination of dichotomous and
continual lung function traits. However, the limitations of
this study include the absence of an independent replica-
tion sample, and that some of the dichotomous analyses
were based on small numbers. The low number of con-
trols versus cases in the dichotomous COPD analysis may
at least in part explain the lack of concordance in findings
generated using the continual lung function traits which
provided more clear evidence for association. It is also
important to note that the current study examines the role
of PLAUR SNPs in the development of airway obstruction
in smokers and does not test the role of PLAUR polymor-
phisms in non smoking individuals.
Conclusion
We provide preliminary evidence that PLAUR SNPs influ-
ence baseline lung function in smokers. However, our
data does not support a significant role for PLAUR SNPs
contributing to the multiple genetic factors that predis-
pose smokers to develop COPD.
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